

Immuno-oncology Market Size to reach USD 195 Billion By 2030 Growing at 20.30% CAGR | GlobalData Plc

LONDON, UK, October 24, 2022 /EINPresswire.com/ -- The global immuno-oncology market was worth nearly \$45,121.62 million in 2021. The immuno-oncology market is expected to grow at a more than CAGR of 20% over the next 10 years. Major factors such as an increase in healthcare expenditure, a rise in the prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost market growth during the forecast period.



Immuno-oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Type (Checkpoint Modulators, Cancer Vaccines) and End-User (Hospitals, Cancer Research Institute), 2022-2030

View Report Outlook at:

https://www.globaldata.com/store/report/immuno-oncology-market-trend-analysis/

The immuno-oncology market report offered by GlobalData Plc provides an overview of the immuno-oncology market size & forecast by class, end-user, and geography. It also helps us understand the immuno-oncology value chain and identify the key vendors in the market.

Learn about the Immuno-oncology Market Dynamics by Viewing Report Sample Right Here!

Immuno-oncology Market Report Highlights

- The global immuno-oncology market is projected to witness a CAGR of 20.30% from 2021 to 2030, reaching a value of \$238.19 billion. Major factors such as an increase in healthcare expenditure, a rise in prevalence and incidence of cancer, a surge in technological advancement in cancer treatment, and novel product launches are expected to boost the market growth during the forecast period
- In 2021, the checkpoint modulators segment of the immuno-oncology market is estimated at US\$36.45 billion in 2021 and is forecast to reach US\$191.38 billion by 2030, growing at a CAGR of

20.23%.

- The hospitals segment of the immuno-oncology market is estimated at \$37.22 billion in 2021 and is expected to grow up to \$195.64 billion by 2030, growing at a CAGR of 20.25%.
- North America closely followed by Europe captured over 60% of the overall immuno-oncology share in 2021. The rise in cancer incidence, approval of novel drug therapies, increasing funding and investment for the development of immuno-oncology drugs, and an increase in strategic partnerships are the major factors contributing to the market growth.
- The immuno-oncology market key players analyzed as part of this report are Amgen, AstraZeneca, Roche, among others

Unlock additional market dynamics impacting the immuno-oncology market growth by Requesting a Sample PDF

GlobalData Plc has segmented the immuno-oncology market report by class, End-user, and region:

Global immuno-oncology class Outlook (Revenue, USD Million, 2022-2030)

- Checkpoint Modulators
- Cancer vaccines
- Cell Therapies
- Bispecific antibodies
- Cytokines
- Oncolytic Viruses

Global immuno-oncology end-user Outlook (Revenue, USD Million, 2022-2030)

- Hospitals
- Cancer Research Centers
- Others

Immuno-oncology market outlook report with detailed segment analysis is available with Global Data Now! <u>Make a Purchase Right Here!</u>

Global Immuno-oncology Regional Outlook (Revenue, USD Million, 2022-2030)

- · North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy

- Spain
- · Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- ROW
- UAE
- · Saudi Arabia
- Brazil
- Rest of ROW

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision-makers to predict and navigate the future. GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on us for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

Mark Jephcott GlobalData Plc +44 20 7936 6400 mark.jephcott@globaldata.com Visit us on social media:

Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/597115249

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.